A deep learning framework combines convolutional and bidirectional recurrent networks to improve protein function prediction from genomic sequences. By automating feature extraction and capturing long ...

Objectives Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive ...

Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

While a majority of the therapies currently in development are life-long treatments, Genespire is taking a different approach ...

Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...

New genetic evidence reveals unexpected killers behind one of history’s deadliest military disasters.

Samsung Biologics expands Korea CRDMO lead with MCB and vector services Samsung Biologics widens CRDMO edge with new MCB and ...

Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...

Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check out why INO stock is a buy.

Under the agreement, Bionova will serve as the preferred manufacturing partner for Syenex’s best-in-class delivery platforms.